BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bioinformatics Software | QIAGEN Digital Insights
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T110000
DTEND;TZID=America/New_York:20231205T120000
DTSTAMP:20260410T141831
CREATED:20231120T172709Z
LAST-MODIFIED:20241024T182953Z
UID:10000709-1701774000-1701777600@staging.digitalinsights.supremeclients.com
SUMMARY:Comprehensive Molecular Tumor Analysis (CMTA) integrating RNAseq and tumor immune microenvironment (TME) for targeted therapy
DESCRIPTION:Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However\, deeper molecular insights are needed to improve personalized treatment decisions that are tailored to specific molecular characteristics of a tumor. Integrating gene expression analysis in personalized oncology provides an additional level of insight that cannot be provided by genomic data alone. These analyses include evaluating expressed mutations and drug targets\, novel gene fusions\, clinically relevant signatures\, and the tumor immune microenvironment (TME). \nComprehensive Molecular Tumor Analysis (CMTA) is a NGS-based innovative tumor diagnostic test developed by Alacris Theranostics. The test integrates whole exome and transcriptomic sequencing (WES and RNAseq) and is deployed as an end-to-end accredited diagnostic platform from tumor sample uptake (FFPE or frozen) to personalized clinical interpretation report. Designed to serve all cancer patients\, CMTA is a tumor-agnostic test that displays a unique molecular view into each individual sample\, which is particularly well-suited to refractory cancers with complex patterns or tumors of unknown origin. \nIn this webinar\, Alacris Theranostics will discuss the benefits of comprehensive tumor profiling in clinical settings and present the strategy implemented in their bioinformatics pipeline to identify cancer-relevant somatic events. In addition\, the diagnostic company will share how they use QIAGEN Clinical Insight (QCI) Interpret to annotate variants and identify potential therapeutic entry-points.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/comprehensive-molecular-tumor-analysis-cmta-integrating-rnaseq-and-tumor-immune-microenvironment-tme-for-targeted-therapy/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1305_6_QDI_QCI_Gi1388387853-3.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231205T130000
DTEND;TZID=America/New_York:20231205T150000
DTSTAMP:20260410T141831
CREATED:20231106T171550Z
LAST-MODIFIED:20241024T182949Z
UID:10000701-1701781200-1701788400@staging.digitalinsights.supremeclients.com
SUMMARY:New user training: Large dataset analysis and knowledge base queries using QIAGEN Ingenuity Pathway Analysis (IPA)
DESCRIPTION:\,\nIn this training\, you’ll learn how to:\n• Upload your dataset (RNA-seq\, scRNA-seq\, proteomics\, metabolomics and more) and perform interactive core/pathway analysis in IPA\n• Understand the different result types produced (pathways\, key regulators\, impact on biological functions/diseases and more)\n• Compare different experimental conditions (treatments\, time points\, single-cell clusters\, disease types and more) and identify similarities and contrasts\n• Generate a network even without a dataset or experimental design for hypothesis generation \nFor those with IPA license\,\nTo install IPA before or after this training\, please use below installer.\nhttps://qiagen.showpad.com/share/CBv30blCPKFDUYHRWtAvI
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/new-user-training-large-dataset-analysis-and-knowledge-base-queries-using-qiagen-ingenuity-pathway-analysis-ipa-6/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/png:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/guy-with-new-IPA-picture.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20231206T140000
DTEND;TZID=Europe/Paris:20231206T150000
DTSTAMP:20260410T141831
CREATED:20231108T121513Z
LAST-MODIFIED:20241024T182949Z
UID:10000702-1701871200-1701874800@staging.digitalinsights.supremeclients.com
SUMMARY:Mining curated knowledge graphs and validating with experimental datasets to accelerate your drug target discovery
DESCRIPTION:In an era of near-limitless public experimental data but little standardization\, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny.  In this webinar\, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Knowledge Base with deeply-curated disease datasets from QIAGEN OmicSoft Lands.  Combining unified 'omics datasets with contextual relationship evidence from our knowledge graph\, we will address complex questions such as: • Which genes aren't expressed in normal tissue\, yet are expressed in diseases of interest\, based on experimental evidence? • Which of these proteins are cell surface proteins\, with evidence for extracellular localization? • How are these proteins related directly or indirectly to disease pathways\, and can these be connected to known drug targets? • Can we identify correlated biomarkers\, mutation targets\, clinical factors or other means of cohort selection?
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/mine-curated-knowledge-graphs-and-validate-with-experimental-datasets-for-drug-target-discovery-3/
LOCATION:Virtual - EMEA - CET
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1052_1_QDI_OmicSoft_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231207T110000
DTEND;TZID=America/New_York:20231207T120000
DTSTAMP:20260410T141831
CREATED:20231115T130508Z
LAST-MODIFIED:20241024T182953Z
UID:10000708-1701946800-1701950400@staging.digitalinsights.supremeclients.com
SUMMARY:Translating COSMIC's gold standard data into actionable insights
DESCRIPTION:As the vast landscape of genetic oncology continues to expand\, the ability to understand and utilize the full potential of this rich data becomes increasingly challenging. As a result\, researchers\, scientists\, and clinicians need an accessible\, streamlined and standardized way of keeping track of this potentially crucial\, ever-growing body of actionable knowledge. Over the course of 20 years\, COSMIC\, the Catalogue Of Somatic Mutations In Cancer\, has expertly curated the world’s largest\, most comprehensive database for somatic mutation information relating to human cancer. Today\, COSMIC is used worldwide by revered research and clinical institutes\, biotech and pharmaceutical companies\, and more.\n\nIn this webinar\, Leonie Hodges\, Scientific Communications Officer for COSMIC\, will delve into the wide range of datasets that COSMIC offers\, detailing the content\, how to obtain actionable insights from the genomic data\, and how to potentially use this data for real-world applications. Following the talk\, there will be a live Q&A with Jennifer Wilding\, Scientist Curator at COSMIC and Alex Holmes\, Senior Database Curator at COSMIC.\n\nBy attending this webinar\, you will learn how to:\n\nExplore the wide range of datasets that COSMIC offers\, including the Cancer Mutation Census and Mutational Signatures;\nGain insights from COSMIC’s gold standard genomic data by taking either a disease or gene centric view of your research;\nIdentify potential applications of COSMIC data and how it enables users from a plethora of disciplines to experiment and innovate with confidence.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/translating-cosmics-gold-standard-data-into-actionable-insights/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1229_4_QDI_QCI_COSMIC_Actionabilityv5.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231207T130000
DTEND;TZID=America/New_York:20231207T140000
DTSTAMP:20260410T141831
CREATED:20231108T121640Z
LAST-MODIFIED:20241024T182950Z
UID:10000703-1701954000-1701957600@staging.digitalinsights.supremeclients.com
SUMMARY:Mining curated knowledge graphs and validating with experimental datasets to accelerate your drug target discovery
DESCRIPTION:In an era of near-limitless public experimental data but little standardization\, meaningful insights are lost to noise. Large collections of quality experimental data are essential for big-picture discoveries that stand up to scrutiny.  In this webinar\, you will learn how to feed your drug discovery programs by integrating connections mined from QIAGEN Biomedical Knowledge Base with deeply-curated disease datasets from QIAGEN OmicSoft Lands.  Combining unified 'omics datasets with contextual relationship evidence from our knowledge graph\, we will address complex questions such as: • Which genes aren't expressed in normal tissue\, yet are expressed in diseases of interest\, based on experimental evidence? • Which of these proteins are cell surface proteins\, with evidence for extracellular localization? • How are these proteins related directly or indirectly to disease pathways\, and can these be connected to known drug targets? • Can we identify correlated biomarkers\, mutation targets\, clinical factors or other means of cohort selection?
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/mine-curated-knowledge-graphs-and-validate-with-experimental-datasets-for-drug-target-discovery-2-2/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1052_1_QDI_OmicSoft_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231212T130000
DTEND;TZID=America/New_York:20231212T140000
DTSTAMP:20260410T141832
CREATED:20231108T122647Z
LAST-MODIFIED:20241024T182950Z
UID:10000704-1702386000-1702389600@staging.digitalinsights.supremeclients.com
SUMMARY:Target exploration and cell line selection for drug discovery
DESCRIPTION:Cancer cell line models have been a cornerstone of cancer research for decades. Cancer cell lines profiling can be a powerful tool for the identification of genes’ alterations or pathways cancer-related and for the discovery of putative drug targets. This webinar will focus using Qiagen OmicSoft Lands and Ingenuity Pathway Analysis as guides for the selection of cell lines and translation of insights gained from cell lines for drug target discovery. \nThis 90-minute event will show how our platform enables scientists:\n• Select appropriate cancer cell lines for a variety of applications such as drug discovery\, precision disease modeling\, understanding gene function in cancer\, immune-oncology research.\n• Examine various ‘omics data for genes of interest for expression\, mutation\, hotspots\, and gene dependency data.\n• Generate networks for hypotheses and test the in-silico to improve translation of insights derived from cell line models to the drug target identification.\n• Integrated analyses of public 'omics data and drug response phenotypes using cell line model systems by exploring data from the Library of Integrated Network-Based Cellular Signatures (LINCS).\n• How to prioritize drug targets and profile phenotypic/downstream effects of drug action by overlaying public data on user generated networks. \nOur system uses millions of curated literature findings in the QIAGEN/ IPA knowledge base and the OmicSoft digital warehouse. The presentation is intended for both those familiar with Ingenuity Pathway and newcomers interested in learning more.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/target-exploration-and-cell-line-selection-for-drug-discovery-2/
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1063_9_OmicSoft-Single-Cell-Lands_028687_16x9.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231213T100000
DTEND;TZID=America/New_York:20231213T110000
DTSTAMP:20260410T141832
CREATED:20231108T123149Z
LAST-MODIFIED:20241024T182953Z
UID:10000706-1702461600-1702465200@staging.digitalinsights.supremeclients.com
SUMMARY:How to perform DNA-seq and resequencing data analyses using QIAGEN CLC Genomics Workbench
DESCRIPTION:In this webinar\, we’ll introduce algorithms required to perform data analysis for resequencing next-generation sequencing data. Together\, we’ll explore:  • Read mapper • Variant callers • Annotations and filters • Genome Browser  Bring any questions you may have\, and we will answer them during the webinar. 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/how-to-perform-dna-seq-data-analysis-with-clc-genomics-workbench-resequencing/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1109_4_QDI_CLC_Challenger_Or55819-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231213T110000
DTEND;TZID=America/New_York:20231213T120000
DTSTAMP:20260410T141832
CREATED:20231201T164654Z
LAST-MODIFIED:20241024T182954Z
UID:10000710-1702465200-1702468800@staging.digitalinsights.supremeclients.com
SUMMARY:One tool to help biopharma accelerate cancer drug discovery and repurposing: A translational research use-case and discussion
DESCRIPTION:The development of new cancer drugs is challenging\, costly\, and time-consuming. As translational research on cancer diagnostics and genomic profiling rapidly evolves\, the ability to confidently and efficiently identify specific oncogenes and tumor suppressors involved in oncogenesis is becoming increasingly difficult. \nThis brief half-hour webinar is intended for biopharmaceutical and biotechnology professionals who need more efficient ways of discovering\, developing\, and repurposing drugs for oncology applications. During the session\, attendees will explore a demonstration and a use-case presented by Dr. Kyle Nilson\, providing insights into the Human Somatic Mutation Database (HSMD)—a new somatic database developed by QIAGEN that contains extensive genomic content relevant to solid tumors and hematological malignancies. \nHSMD is an exceptional resource for biopharmaceutical and biotechnology companies\, facilitating the confident evaluation of cancer-related genetic variations by granting access to real-world data. Powered by QIAGEN’s extensive artificial intelligence (AI)-enabled Knowledge Base\, robust curation team composed of over 100 expert curators (MD and PhD level)\, and data from QIAGEN’s professional variant interpretation service (previously N-of-One)\, HSMD encompasses a vast repository of over 4.7 million meticulously curated genetic alteration findings and variant data over 500\,000 somatic patient cases. Attendees will explore how HSMD enables biopharmaceutical and biotechnology companies to gain deeper insights into the molecular cancer profiles\, identify therapeutic options\, and develop strategies for finding new therapies for a particular cancer type or even for a particular patient. \nAttendees will: \n\nLearn what content sources power HSMD\nUnderstand how to use and apply HSMD for multiple applications\, including translational research and pharmaceutical development\nExamine a use case of how to use HSMD to accelerate research\, development and repurposing in cancer drug development programs\nReceive a complimentary 5-day trial of HSMD
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/one-tool-to-help-biopharma-accelerate-cancer-drug-discovery-and-repurposing-a-translational-research-use-case-and-discussion/
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1144_5_QDI_QCI_HSMD_GI646221430_16x9_59476_Large-1200px-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231214T130000
DTEND;TZID=America/New_York:20231214T150000
DTSTAMP:20260410T141832
CREATED:20231108T123505Z
LAST-MODIFIED:20241024T182952Z
UID:10000705-1702558800-1702566000@staging.digitalinsights.supremeclients.com
SUMMARY:RNA-seq data analysis and interpretation with sankey plot update
DESCRIPTION:During this 120-minute training\, we’ll teach you how to easily analyze and interpret RNA-seq data using QIAGEN CLC Genomics Workbench and QIAGEN Ingenuity Pathway Analysis (IPA) software.  For RNA-seq data\, you will learn how to: • Import FASTQ files\, cell-matrix files and metadata and how to download references • Map reads to a reference genome and generate gene and transcript counts and QC reports displaying % mapped reads\, knee plots\, etc. • Generate visualizations of results\, such as heatmaps\, differential expression tables\, PCA/PCOA plots\, Venn diagrams\, sankey plot and others • Easily customize RNA-seq workflows • Export publication-quality graphics\, tables and reports • Send differential expression tables to QIAGEN Ingenuity Pathway Analysis directly from QIAGEN CLC Genomics Workbench to analyze and interpret relevant pathways  Here you can explore the types of analyses and visualizations you'll learn to generate (slides from previous training): https://qiagen.showpad.com/share/qiZLmCUS32GZNM1B4llMf 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/rna-seq-data-analysis-and-interpretation-with-sankey-plot-update/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Training
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1140_5_QDI_CLC_V22_16x9_Large-1200px_58739.jpg
END:VEVENT
END:VCALENDAR